Adverse events of iron and/or erythropoiesis-

stimulating agent therapy in preoperatively anaemic

elective surgery patients: a systematic review

- 4 Author names and affiliations
- Jorien Laermans^{1*}, Hans Van Remoortel¹, Bert Avau¹, Geertruida Bekkering^{2,3,8}, Jørgen Georgsen⁴,
- Paola Maria Manzini⁵, Patrick Meybohm⁶, Yves Ozier⁷, Emmy De Buck^{1,8}, Veerle Compernolle^{9,10},
- 7 Philippe Vandekerckhove^{8,11,12}
- 8 ¹ Centre for Evidence-Based Practice, Belgian Red Cross, Mechelen, Belgium
- ² Center for Evidence-Based Medicine, Leuven, Belgium
- 10 ³ Cochrane Belgium, Leuven, Belgium
- ⁴ South Danish Transfusion Service, Odense University Hospital, Odense C, Denmark
- 12 ⁵ SC Banca del Sangue Servizio di Immunoematologia, University Hospital Città della Salute e della
- 13 Scienza di Torino, Torino, Italy
- ⁶ Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital
- 15 Wuerzburg, Wuerzburg, Germany
- ⁷ University Hospital of Brest, Brest, France
- 17 Begartment of Public Health and Primary Care, Faculty of Medicine, KU Leuven, Leuven, Belgium
- 18 ⁹ Belgian Red Cross, Blood Services, Mechelen, Belgium
- 19 ¹⁰ Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
- 20 ¹¹ Belgian Red Cross, Mechelen, Belgium
- 21 ¹² Centre for Evidence-Based Health Care, Stellenbosch University, Cape Town, South Africa
- 23 * Corresponding author

22

24

- 25 E-mail addresses: jorien.laermans@cebap.org (JL), hans.vanremoortel@cebap.org (HVR)
- bert.avau@cebap.org (BA), trudy.bekkering@kuleuven.be (GB), georgsen@dadlnet.dk (JG),
- 27 paola.manzini@gmail.com (PMM), Meybohm P@ukw.de (PM), yves.ozier@gmail.com (YO),

28 <u>emmy.debuck@cebap.org</u> (EDB), <u>veerle.compernolle@rodekruis.be</u> (VC),

philippe.vandekerckhove@rodekruis.be (PV)

Abstract

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Background. Iron supplementation and erythropoiesis-stimulating agent (ESA) administration represent the hallmark therapies in preoperative anaemia treatment, as reflected in a set of evidencebased treatment recommendations made during the 2018 International Consensus Conference on Patient Blood Management. However, little is known about the safety of these therapies. This systematic review investigated the occurrence of adverse events (AEs) during or after treatment with iron and/or ESAs. **Methods.** Five databases (The Cochrane Library, MEDLINE, Embase, Transfusion Evidence Library, Web of Science) and two trial registries (ClinicalTrials.gov, WHO ICTRP) were searched until November 6 2020. Randomized controlled trials (RCTs), cohort and case-control studies investigating any AE during or after iron and/or ESAs administration in adult elective surgery patients with preoperative anaemia were eligible for inclusion, and judged using the Cochrane Risk of Bias tools. The GRADE approach was used to assess the overall certainty of evidence. Results. 26 RCTs and 16 cohort studies involving a total of 6062 patients were included, providing data on 6 comparisons: (1) Intravenous (IV) versus oral iron, (2) IV iron versus usual care/no iron, (3) IV ferric carboxymaltose versus IV iron sucrose, (4) ESA+iron versus control (placebo and/or iron, no treatment), (5) ESA+IV iron versus ESA+oral iron, and (6) ESA+IV iron versus ESA+IV iron (different ESA dosing regimens). Most AE data concerned mortality/survival (n=24 studies), thromboembolic (n=22), infectious (n=20), cardiovascular (n=19) and gastrointestinal (n=14) AEs. Very low-certainty of evidence was assigned to all but one outcome category. This uncertainty results from both low quantity and quality of AE data due to high risk of bias caused by limitations in study design, data collection and reporting. Conclusions. It remains unclear if ESA and/or iron therapy is associated with AEs in preoperatively anaemic elective surgery patients. Future trial investigators should pay more attention to the systematic collection, measurement, documenting and reporting of AE data.

Keywords

57

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

- 58 Systematic review, elective surgery, anaemia, preoperative care, haematinics, erythropoiesis-
- 59 stimulating agents, iron, blood transfusion, adverse events

Introduction

Transfusion of blood components can be a life-saving intervention, but comes with the risks of transfusion reactions and transmission of bloodborne infections. To optimize the care of patients who might need transfusion and minimize the patient's exposure to allogeneic blood products, a multidisciplinary approach has been developed and termed 'Patient Blood Management' (PBM)(1). PBM encompasses all aspects surrounding the transfusion decision-making process through three pillars: (1) addressing pre-existing preoperative anaemia, (2) minimizing intraoperative blood loss, and (3) applying appropriate transfusion triggers to ensure rational allogeneic blood product use. In an attempt to analyse the scientific evidence on all PBM aspects through systematic literature searches, and reach international consensus using transparent, rigorous and quality-controlled decision-making, an international consortium of scientific organizations in the field of blood transfusion coordinated a consensus meeting on evidence-based PBM. During this 2018 International Consensus Conference on Patient Blood Management (ICC-PBM), a set of 10 clinical and 12 research recommendations were formulated using the GRADE methodology (2, 3). One PBM pillar focusses on addressing pre-existing preoperative anaemia. Preoperative anaemia is associated with increased perioperative blood transfusion requirements, increased risk of perioperative infection, mortality, postoperative complications and extended hospital stay (4-7). During the ICC-PBM, four clinical recommendations (Table 1) were formulated concerning the treatment of preoperative anaemia, using iron supplementation (in case of iron-deficiency anaemia) and/or erythropoiesis-stimulating agents (ESAs) (2).

Table 1. Clinical recommendations formulated during the ICC-PBM as published previously (2).

Clinical recommendation	Strength of recommendation and certainty of
	evidence

1.	Detection and management of preoperative	Strong recommendation, low-certainty evidence
	anaemia early enough before major elective	
	surgery	
2.	Use of iron supplementation to reduce red	Conditional recommendation, moderate-
	blood cell transfusion rate in adult	certainty evidence
	preoperative patients with iron-deficient	
	anaemia undergoing elective surgery	
3.	Do not use erythropoiesis-stimulating agents	Conditional recommendation, low-certainty
	routinely in general for adult preoperative	evidence
	patients with anaemia undergoing elective	
	surgery	
4.	Consider short-acting erythropoietins in	Conditional recommendation, low-certainty
	addition to iron supplementation to reduce	evidence
	transfusion rates in adult preoperative	
	patients with hemoglobin concentrations <	
	13 g/dL undergoing elective major	
	orthopaedic surgery	

As effectiveness is just one aspect to consider in making a balanced treatment recommendation, the expert panel recommended to investigate the use of short-acting erythropoietins and iron supplementation in adult preoperative patients undergoing elective surgery, with focus on long-term (un)desirable effects, optimal dose, type of surgery (particularly in cancer surgery), copresence of iron deficiency, and cost-effectiveness (2).

Therefore, in a follow-up project, three full systematic reviews were conducted to gather the best available scientific evidence on the effectiveness (review 1)(8), safety (review 2) and cost-effectiveness (review 3)(9) of iron and/or ESA therapy in adult patients with preoperative anaemia undergoing elective surgery. The current systematic review (review 2) focused on the occurrence of adverse events (AEs) during or after treatment with iron and/or ESAs.

Methods

95

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

96 This systematic review was not prospectively registered, but was carried out in accordance with the

pre-defined methodological standards of the Centre for Evidence-Based Practice (10). Eligibility

criteria and data synthesis plans were established a priori by the reviewers (JL and HVR) and

approved by a third external methodological expert (GB) and 4 PBM experts (JG, PM, PMM, YO).

The reporting of this review adheres to the PRISMA harms checklist (11) (completed checklist in

Additional file 1).

Eligibility criteria

This review's PICO question was: "In elective surgery patients with preoperative anaemia (P), is the

use of iron and/or ESA therapy (I), linked to AEs (O)?".

Population

Anaemic adults (≥18 years) scheduled for elective surgery were eligible for inclusion. Studies were

included if the baseline haemoglobin (Hb) levels of the study participants were in line with the World

Health Organization (WHO) criteria for anaemia, i.e. <13 g/dl for men and <12 g/dl for women.

Different criteria for anaemia were accepted if the study investigators provided a clear definition of

anaemia, or if no clear definition was provided but baseline Hb levels were <13 g/dl in all patients

(based on the upper limit of the 99% confidence interval (CI) (mean Hb levels) or the 75th percentile of

the Interquartile Range (IQR) (median Hb levels)). Studies in pregnant women, children and non-

elective surgery patients were excluded.

Intervention

Studies were eligible if they investigated the administration effect of iron and/or ESAs, regardless of

treatment dose, duration and formulation (enteral or parenteral). Studies were only included if the

administration was started, but not necessarily ended, during the preoperative period. If patients

received other cointerventions (e.g. vitamins, folic acid, heparin), the study was only included if these

cointerventions were identically administered to both (intervention and control) groups.

Comparison

Studies were included if they compared the intervention(s) of interest to at least one of the following control groups: placebo, no treatment, standard of care (as per each trial protocol), iron monotherapy, other type of iron therapy (e.g. IV versus oral), or other ESA dosing regimen.

Outcome

AEs were defined as "unfavourable or harmful outcomes that occur during, or after, the use of a drug or other intervention, but are not necessarily caused by it" (12).

Any AE occurring during/after iron and/or ESA administration was eligible for inclusion and classified by the reviewers (JL and HVR), a third external methodological expert (GB) and 4 PBM experts (JG, PM, PMM, YO) in one of 15 categories (listed in Table 2). The classification system of Szebeni, 2015 (13) served as a starting point and was supplemented with additional categories until consensus with the PBM experts was reached.

Table 2. Adverse event categories.

Adverse event category	Examples of individual adverse events					
Gastrointestinal	Diarrhea					
	Constipation					
	Dyspepsia					
	Nausea					
Mucocutaneous	Rash					
	Urticaria					
	 Erythema 					
	• Palor					
Autonomic	• Fever					
Neuro-psychosomatic	Myalgia					
	Injection pain					
	Headache					
Neurological	Postoperative ileus					
	 Vertigo 					
	Dysgeusia					

Wound healing	Poor wound healing
3	
	Delayed wound healing
Bronchopulmonary	Dyspnea
	Respiratory failure
Infectious	Surgical wound infection
	Urinary tract infection
	Septic shock
	 Pneumonia
Bleeding	Upper gastrointestinal bleed
Cardiovascular	Atrial fibrillation
	Cardiac tamponade
	Hypertension
	Tachycardia
Renal	Need for renal replacement therapy
Anaemia-associated ischemic	Myocardial infarction
	Myocardial ischemia
	Stroke
	Transient ischemic attack
	Bowel ischemia
	Acute kidney injury
	Acute limb ischemia
Thromboembolic	Deep venous thrombosis
	Pulmonary embolism
	Other thrombotic events
Mortality and survival	Mortality
	Survival
Other	Muscle spasms
	 Allergy
	Convulsions

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

Need for reoperation AEs were classified into 15 categories (based on the classification system by Szebeni, 2015 (13)). Examples of individual adverse events listed are non-exhaustive, except for the anaemia-associated ischemic and thromboembolic events. Study design Since many AEs are too uncommon or long-term to be observed within randomized trials (12), both controlled experimental studies (e.g. RCTs) as well as observational cohort and case-control studies were included. **Publication status** Published and non-published data were included. Study authors of ongoing or prematurely ended registered trials were contacted to obtain the expected completion/publication date or reason for termination (if not specified). Other criteria No date or language restrictions were applied. Data sources and searches The following databases and trial registries were searched from inception up to November 6 2020 (search date: November 6 2020): The Cochrane Library (Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials), MEDLINE (using the PubMed interface), Embase (using the Embase.com interface), Transfusion Evidence Library, Web of Science, WHO International Clinical Trials Registry Platform and Clinicaltrials.Gov. Search strings comprising both index terms and free text words were tailored to each database (Supplementary Table 1 in Additional file 2). Reference lists and the 20 first related citations in PubMed of the included records were scanned for additional studies.

Study selection

Two reviewers (JL and HVR) independently screened the title and abstracts and subsequently the full-

texts of the identified references guided by the eligibility criteria, using the EPPI-Reviewer Web

software (14). Discrepancies were resolved by discussion. Where necessary, a third reviewer was

consulted (BA).

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

As AE data are notorious for their incomplete/poor reporting, study authors of studies that did not

report on AEs but did meet the other eligibility criteria were contacted via email at least twice. If the

authors confirmed that no AE data were collected, or did not reply, the study was excluded. If the

authors supplied the reviewers with unpublished findings on AEs, the study was included.

Data extraction

Data extraction was performed independently by two reviewers (JL and HVR). For each individual study, the following data were extracted: source (peer-reviewed publication: author, publication year and country; trial registration: trial registry number), study design, description of the population, definition of anaemia and iron-deficiency applied by the study investigators, intervention(s), comparison(s), co-interventions, red blood cell transfusion trigger applied, AE outcome(s) of interest (+ method and timing of outcome assessment), raw event data for each of the reported AEs. If a study presented its data as both composite measures (e.g. 'cardiovascular complications') and separate individual AEs (e.g. 'atrial fibrillation' and 'cardiac tamponade'), only the individual data were extracted. If a preregistered trial protocol was available, the trial registration webpage was scanned for additional information (e.g. End of Study Reports). In case of missing or insufficiently ambiguous data or composite measure data, study authors were contacted via email at least twice regarding additional or disaggregated data. If a study reported a general statement indicating the absence of an AE (e.g. "no serious AEs were identified in any group," without defining seriousness), this was considered insufficiently ambiguous and authors were contacted to confirm the absence of events (true "zero events"), and to clarify the individual AEs that were studied/recorded. If they did not reply or were not able to specify the events, the study was excluded.

Quality appraisal: risk of bias and GRADE assessment

Risk of bias and GRADE assessments were performed by two reviewers independently (JL and HVR). Discrepancies were resolved through discussion. The GRADE assessment was verified by a third external methodological expert (GB). Risk of bias at the study level was assessed using the Cochrane risk-of-bias tool for randomized trials (15) or the GRADE key criteria for observational study limitations ('Inappropriate eligibility criteria', 'Inappropriate methods for exposure variables', 'Not controlled for confounding', 'Incomplete or adequate follow-up', 'Other limitations') for experimental and observational studies, respectively, except for the items regarding 'Inadequate measurement of the outcomes' and 'Inadequate selection of the reported results'. For these items, domains 4 and 5 of the revised Cochrane risk-of-bias tool (RoB 2) (16) were used, as they cover the important aspects for assessing bias in AE studies more thoroughly. The signaling questions were answered in the Excel RoB 2 implementation tool (17). Whenever the tool's algorithm proposed 'low', the reviewers judged the study at low risk of bias. If the algorithm proposed 'some concerns' or 'high', they judged it at high risk of bias. Next, the GRADE approach (Grading of Recommendations, Assessment, Development and Evaluation) was used to assess the overall certainty of the evidence. The certainty of the evidence for each outcome (category) was graded as 'high', 'moderate', 'low' or 'very low'. Experimental and observational studies receive an initial grade of 'high' and 'low', respectively. Subsequently, these initial levels may be downgraded (based on risk of bias, imprecision, inconsistency, indirectness, and selective non-reporting bias) or upgraded (based on large effect, dose-response gradient, plausible confounding)(18).

Data synthesis

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

If at least 2 studies provided data on the same outcome within the same treatment comparison, and no large heterogeneity in outcome definitions and measurements was suspected, random effects meta-analysis was performed using the Review Manager 5.3 software (19). Heterogeneity was assessed through visual inspection of the forest plot and by using the X²-test and the I² statistic. To investigate if AEs varied by administration route (i.e. oral versus IV iron), subgroup analyses were performed. Predefined sensitivity analyses were done to explore the influence of: (1) different definitions of anaemia, and (2) different risk of bias judgements concerning 'Inadequate measurement

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

of the outcomes' and 'Inadequate selection of the reported results' (see Quality appraisal). The statistical significance threshold was set at 5%. In case a meta-analysis was not possible (i.e. data were only reported by one study) or warranted (i.e. heterogeneity in outcome definitions was observed or suspected), outcome data were presented in a single forest plot per AE category (without calculating a total effect size) as a visual aid for result interpretation. Statistical synthesis of these results was deemed inappropriate and no statements about consistency of effects across studies or outcomes were made to avoid unintentional vote counting (20). To formulate the overall review findings as clearly and simply as possible, informative statements were developed in accordance with the set of statements provided by the GRADE Working Group and the Cochrane GRADEing Methods Group (21, 22). Results Search results Figure 1 shows the detailed PRISMA study selection flow diagram. The primary search yielded 10142 database records and 3163 trial registry records. After duplicate removal, the title and abstract of the remaining 8221 records were screened. After full text screening and resolving disagreements, 44 peer-reviewed publications and 3 clinical trial study reports reporting on 42 unique studies were included. A list of studies excluded during full text screening and the reasons for exclusion is provided in Supplementary Table 2 in Additional file 2. Moreover, we identified 21 unique relevant registered ongoing trials (24 trial registrations) and 6 unique prematurely ended or terminated trials (7 registrations), as well as 2 relevant protocol papers (Supplementary Table 3 in Additional file 2). Figure 1. PRISMA study selection flow diagram. WHO: World Health Organization; ICTRP: International Clinical Trials Registry Platform Study characteristics Of the 42 included studies involving a total of 6062 patients, 26 were RCTs (23-50) and 16 were cohort studies (51-66). Twenty-eight studies were conducted in Europe (Denmark, France, Germany, Greece, Italy, Spain, Sweden, The Netherlands, UK), whereas the other 14 were conducted in

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

Australia (n=2) (30, 35), USA & Canada (n=6) (26, 45, 47, 48, 52, 53) and Asia (China & South Korea (n=6)) (24, 36, 39, 50, 66). Only 15 studies (27, 30, 32, 33, 41, 44, 46, 48, 50, 51, 54, 57, 59, 61-63) applied the WHO definition of anaemia in determining patient study eligibility. Information on the patients' iron-deficiency status was available from just over half the studies (55%) (23, 24, 26, 28-31, 34-36, 38-41, 44, 48, 50, 54, 55, 58, 59, 61, 63). In 8 studies, the entire study population suffered from iron-deficiency anaemia (30, 35, 36, 38, 39, 58, 61, 63). Patients were scheduled for the following types of elective surgery: colorectal cancer (n=12 studies)(25, 27, 31-34, 37, 42, 43, 56, 58, 61, 64, 65), orthopaedic (n=10)(23, 24, 26, 35, 40, 46, 52, 53, 60, 62), cardiac (n=7)(41, 48-51, 55, 57), gynaecologic (n=6)(28, 29, 36, 38, 39, 66), major head and neck oncologic (n=1)(45), abdominal (n=2)(30, 44), spinal (n=1)(47), vascular (n=1)(59)cardiac/thoracic/orthopaedic/gynaecologic/obstetric (n=1)(54)visceral/vascular/gynaecologic/maxillofacial/cardiac/orthopedic/urologic/other major (n=1)(63) surgery. Studies provided data on 6 different treatment comparisons. The majority of the studies (n=22; 52%) reported on the comparison of the combined therapy of ESAs and iron versus control (placebo and/or iron, no treatment) (24-26, 28, 29, 31, 34, 37, 38, 40, 42, 43, 45-53, 60, 66). Seven studies compared IV to oral iron monotherapy (27, 32, 33, 35, 36, 40, 41, 61). Data on the comparison of IV iron monotherapy versus control (usual care or no iron therapy) were provided by 12 studies (30, 44, 54-59, 63-66). Two RCTs compared the combined therapy of ESA+IV iron to that of ESA+oral iron (23, 40), whereas one cohort compared different dosing regimens of ESA during the combined therapy with IV iron (62). Finally, one RCT compared IV ferric carboxymaltose to IV iron sucrose monotherapy (39).Most commonly, AE data concerned mortality/survival (n=24 studies) and the occurrence of thromboembolic (n=22), infectious (n=20), cardiovascular (n=19), gastrointestinal (n=14) and anaemia-associated ischemic AEs (n=10). Autonomic (n=8), bronchopulmonary (n=8), bleeding (n=7), renal (n=7), neuro-psychosomatic (n=6), mucocutaneous (n=6), neurological (n=5), AEs related to wound healing (n=4) and other types of AEs (n=24) were reported by less than 20% of the studies. Supplementary Table 4 in Additional file 2 provides an overview of the AE outcomes for which data were obtained and additionally depicts which RCTs provided data on these outcomes within the 6 treatment comparisons. An similar overview depicting which cohort studies provided data for each of the outcomes within the 6 treatment comparisons is provided in Supplementary Table 5 in Additional

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

file 2. These tables clearly indicate that for any given AE outcome and treatment comparison, data were provided by a very limited number of studies, with the exception of deep venous thrombosis and mortality. In addition, some studies provided data on a multitude of outcomes, whereas others only studied (or at least reported on) a single outcome. Detailed information on the characteristics of the included studies, including the specific AE outcomes and method and timing of their measurement, is presented in Supplementary Table 6 in Additional file 2. Risk of bias and certainty of evidence Risk of bias in the individual studies is presented in Figures 2 and 3 (details in Supplementary Table 7 in Additional file 2). All but two RCTs (27, 49) and two cohort studies (55, 65) were found to be at high risk of bias in outcome measurement. Often, there was insufficient information available to determine if the measurement of the outcome was a pre-defined part of the study protocol or if data were added post-hoc (e.g. by analysing data on AE that must be reported to regulatory agencies such as the FDA). In addition, many studies failed to clearly mention the methods used for (some of) the actual outcome measurement, if these methods used were similar across all study participants, and if the outcome assessors were blinded. Only four RCTs (24, 27, 30, 47) and two cohort studies (55, 65), were judged to be at low risk of bias in the selection of reported results. Often, trial protocols or published papers did not describe how (expected or unexpected) adverse outcomes were collected and analysed. Therefore, the reported AE data may have been selected based on the finding being noteworthy. Figure 2. Risk of bias graph. Review authors' judgments about each risk of bias item presented as percentage across all included (A) RCTs and (B) cohort studies. Figure 3. Risk of bias summary. Review authors' judgments about each risk of bias item for each included (A) RCT and (B) cohort study. ● Low risk of bias, ? Unclear risk of bias, ● High risk of bias Furthermore, 23% of the RCTs were at high risk of performance bias due to lack of blinding of study participants or personnel, whereas only 2 studies showed high risk of attrition bias. Random sequence generation, allocation concealment and blinding of study participants or personnel were unclear in 27%, 50% and 38% of the RCTs, respectively. Furthermore, none of the cohort studies adequately

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

controlled for confounding, and 10 of them applied inappropriate eligibility, whereas the other 6 did not report sufficient information to make an appropriate judgement. Based on the risk of bias assessment of the individual studies, the overall certainty of the entire body of evidence was downgraded by one level for each outcome (category) of treatment comparisons 2 to 6 (see Synthesis of results). Within the first treatment comparison (IV vs oral iron monotherapy), most outcomes were also downgraded by one level based on risk of bias assessment, except for 'survival'. For this outcome, the reviewers found no reason to downgrade because of the well-designed and executed RCT of Dickson et al. (27). Next, for all outcomes within the 6 treatment comparisons, the evidence was further downgraded by 2 levels due to imprecision because of the very low number of AEs, limited sample sizes and the wide 95% CIs around the effect estimates. As a result, a very low certainty of evidence was assigned to all AE outcomes within treatment comparisons 2 to 6, indicating that we are uncertain about these effect estimates. Within the first treatment comparison, the overall certainty for 'survival' was judged to be low, in contrast to the other outcomes that were assigned a very low certainty of evidence. Synthesis of results Supplementary Table 8 in Additional file 2 contains all AE outcome data extracted from the 42 included studies, classified into the 15 AE categories within the 6 treatment comparisons. Metaanalysis could only be performed for a total of 26 outcomes across 3 treatment comparisons: dyspepsia, postoperative infection and mortality (Comparison 1: IV versus oral iron monotherapy), nausea, headache, ileus, dyspnoea, surgical/superficial wound infection, deep venous thrombosis, mortality, hospital readmission (Comparison 2: IV iron vs usual care/no iron) and 15 outcomes within Comparison 4 on ESA+iron versus control (details listed below). For the vast majority of outcomes, meta-analysis was not warranted or feasible. Causality assessment (67) was not feasible, as insufficient information was available to judge the relation between the intervention and the AEs reported, i.e. if AEs were related/probably related/possibly related/unlikely to be related/conditionally related to the studied intervention. Comparison 1: IV vs oral iron monotherapy (7 studies, 312 participants)

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

Neither the meta-analyses on dyspepsia, postoperative infection and mortality data, nor the other separate analyses on any of the other available AE data (36 outcomes across 13 AE categories, detailed in Supplementary Table 8 in Additional file 2) revealed a statistically significant difference in the occurrence when administering IV compared to oral iron monotherapy. Comparison 2: IV iron vs usual care/no iron (12 studies, 2298 participants) One RCT revealed that IV iron monotherapy was associated with a statistically significantly lower readmission rate for wound infection between discharge and 8 weeks, compared to usual care/no iron therapy (44). One cohort study showed that IV iron monotherapy was associated with a statistically significantly lower occurrence of dyspepsia, as well as a statistically significantly lower 1-year infection rate and prevalence of infectious-related codes during hospital stay, compared to usual care/no iron therapy (54). Another cohort study showed that IV iron monotherapy was associated with statistically significantly lower 4-year and 5-year disease-free survival rates, as well as 4-year and 5-year overall survival rates, compared to usual care/no iron therapy (65). Data on the following 8 AE outcomes were meta-analysed: nausea, headache, ileus, dyspnoea, surgical/superficial wound infection, deep venous thrombosis, mortality and hospital readmission. The meta-analysis on the dyspnoea data, provided by two cohort studies (54, 63), showed that IV iron monotherapy was associated with statistically significantly lower occurrence of dyspnoea, compared to usual care/no iron therapy. None of the other meta-analyses, nor the other separate analyses on any of the other available AE data (69 outcomes across 15 categories) revealed a statistically significant difference in the occurrence when administering IV iron monotherapy compared to usual care/no iron therapy. Comparison 3: IV ferric carboxymaltose vs IV iron sucrose monotherapy (1 study, 101 participants) One RCT could not reveal a statistically significant difference in mortality or the occurrence of anaphylactic reactions when administering IV ferric carboxymaltose monotherapy compared to IV iron sucrose monotherapy (39). Data on AEs in the other 13 AE categories were not available.

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

Comparison 4: ESA+iron vs control (placebo and/or iron, no treatment) (22 studies, 3152 participants) One cohort study revealed that the combined therapy of ESA and IV iron was associated with a statistically significantly lower occurrence of acute renal failure, severe infection (composite measure of sepsis, pneumonia or mediastinitis) and major adverse cardiovascular events (composite measure), compared to no treatment (51). In addition, one RCT showed that the combined therapy of ESA and IV iron was associated with a statistically significantly lower postoperative complication rate (composite measure of anastomotic leak abscess/fistula formation, haemorrhage, wound infection, pulmonary complications, complications from blood transfusions), compared to the combination of placebo and IV iron therapy (37). One RCT showed that the combined therapy of ESA and oral iron was associated with a statistically significant higher occurrence of back pain, compared to the combination of standard of care and oral iron therapy (47). Data on the following 15 AE outcomes were meta-analysed: 3 gastrointestinal AEs (nausea, vomiting and obstipation), 2 infectious AEs (surgical/superficial wound infection and urinary tract infection), 4 cardiovascular AEs (atrial fibrillation, heart failure, hypertension and cardiac tamponade), 3 anaemiaassociated ischemic AEs (acute kidney injury, myocardial infarction and stroke; see Figure 4), 2 thromboembolic AEs (pulmonary embolism and deep venous thrombosis; see Figure 5) and mortality. Interestingly, the meta-analysis on the mortality data provided by two small cohort studies (51, 60) showed that the combined therapy of ESA and IV iron was associated with a statistically significantly lower mortality rate compared to control (Risk Ratio (RR): 0.39, 95%CI [0.17;0.91], p=0.03), while this could not be demonstrated by the meta-analysis of the mortality data provided by two RCTs (37, 40) (RR: 0.48, 95%CI [0.21;1.09], p=0.08). When combining all RCTs (25, 31, 34, 37, 40, 45, 49, 53) comparing the combined therapy of ESA and iron (both oral and IV) to control in one meta-analysis, a statistically significant difference in mortality could not be demonstrated. None of the other meta-analyses, nor the other separate analyses on any of the other available AE data (90 outcomes across 14 categories) revealed a statistically significant difference in the

occurrence when administering ESA+iron compared to control.

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

Figure 4. Meta-analyses on myocardial infarction (MI) and stroke (S) during ESA + iron treatment. Meta-analysis of data from RCTs on the occurrence of (A) myocardial infarction and (B) stroke in preoperatively anaemic patients scheduled for elective surgery undergoing the combined treatment therapy of ESA and iron, compared to a control (placebo and/or iron) or no treatment. Figure 5. Meta-analyses on deep venous thrombosis (DVT) during ESA + iron treatment. Metaanalysis of data from RCTs on the occurrence of deep venous thrombosis in (A) RCTs and (B) cohort studies of preoperatively anaemic patients scheduled for elective surgery undergoing the combined treatment therapy of ESA and iron, compared to a control (placebo and/or iron) or no treatment. The findings related to atrial fibrillation and myocardial infarction were not influenced by excluding studies that were not in line with the WHO definition of anaemia. To investigate if AEs differentially occurred during treatment with ESA+IV iron and ESA+oral iron, subgroups were created if possible. Subgroup analyses were performed for 3 cardiovascular AEs (atrial fibrillation, heart failure, hypertension), 2 anaemia-associated ischemic AEs (myocardial infarction, stroke), deep venous thrombosis and mortality. The only statistically significant difference was detected for the outcome of mortality reported by the RCTs, but there was considerable heterogeneity (p-value X²-test = 0.03, I²=78.8%). Two small RCTs (117 participants) that used ESA+IV iron as a treatment (37, 40) reported a lower mortality in the intervention group compared to the control group (Risk Ratio (RR): 0.48, 95%CI [0.21;1.09], p=0.08), whereas the 6 RCTs (1054 participants) that used ESA+oral iron (25, 31, 34, 40, 45, 49) demonstrated non-significantly higher mortality rates in the intervention group (RR: 1.75, 95%CI [0.76;4.02], p=0.18). This betweensubgroup heterogeneity may result from the difference in sample size of and the follow-up period applied by the studies. Comparison 5: ESA+IV iron vs ESA+oral iron (2 studies, 158 participants) One RCT revealed that the combined therapy of ESA and IV iron was associated with statistically significantly less digestive complications, compared to the combined therapy of ESA and oral iron (23). Statistically significant differences in the occurrence of preoperative prostatitis, cardiac or respiratory failure, deep venous thrombosis or preoperative femoral vein thrombosis, thrombotic

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

and/or vascular events, study mortality or mortality during hospitalization, when using the combined therapy of ESA and IV iron compared to ESA and oral iron, could not be demonstrated (23, 40). For 10 AE categories, data were not available. Comparison 6: ESA+ IV iron vs ESA+IV iron (different ESA dosing regimens) (1 study, 127 participants) The only included cohort study (62) could not reveal a statistically significant increase in the occurrence of intestinal obstruction, 3 bronchopulmonary AEs (pulmonary edema, the need for reintubation, the need for prolonged ventilation), 3 infectious AEs (pneumonia, wound infection, urinary tract infection), 2 bleeding AEs (hemorrhagic shock, postoperative hematoma), 4 cardiovascular AEs (atrial fibrillation, acute coronary syndrome, arrhythmia, cardiac arrest), 3 anaemia-associated ischemic AEs (acute limb ischemia, stroke, acute kidney injury), 2 thromboembolic AEs (deep venous thrombosis, pulmonary embolism), epileptic seizures or allergy when comparing different ESA dosing regimens during the combined treatment of ESA and IV iron. Data on AEs in the other 7 AE categories were not available. **Discussion** This systematic review identified 42 studies containing data on AEs occurring during/after the treatment with iron and/or ESAs, classified into 15 AE categories within 6 treatment comparisons. Regarding iron monotherapy: IV iron monotherapy may not be associated with changes in survival compared to oral iron monotherapy (low-certainty evidence). We are uncertain (all very low-certainty evidence) whether: o IV iron monotherapy is associated with an increased occurrence of AEs compared to oral iron monotherapy, or compared to usual care/no iron therapy. IV ferric carboxymaltose monotherapy is associated with an increased occurrence of AEs compared to IV iron sucrose monotherapy. Regarding the combination treatment with ESAs and iron, we are uncertain (all very-low certainty evidence) whether:

 The combined administration of ESAs and iron is associated with an increased occurrence of AEs compared to placebo and/or iron or no treatment.

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

- The combined administration of ESAs and IV iron is associated with an increased occurrence of AEs compared to treatment with ESAs and oral iron.
- The use of different ESA dosing regimens during the combination treatment with ESAs and IV
 iron is associated with differences in the occurrence of AEs.

The majority of the overall certainty of the evidence was judged to be very low due to three main reasons. Firstly, the incidence of many of the studied AEs is low, thereby hindering the precision of the results. For example, incidence rates of anaphylactic reactions after IV iron administration are reported to lie around 0.1-1% (68, 69). Hence, several hundreds of patients would have been required to detect a difference between IV ferric carboxymaltose and IV iron sucrose patients in the study by Lee (39). The issue of low incidence is also illustrated in Figure 5 on deep vein thrombosis. In 4 of the 10 studies (31, 42, 52, 53), deep venous thrombosis was detected in just one treatment participant. Two other studies (45, 46) did not detect deep venous thrombosis in any of the treatment or control group participants. Although this highlights the successful use of thromboprophylaxis, the small number of events decreases the precision of the estimate and therefore renders the results fragile (70). A closer look at the entire dataset of treatment comparison 4 reveals that 17 of the 22 studies did not observe any event in the treatment group for at least one of their studied AEs (45 in total). The issue is further complicated by the fact that in 20% and 36% of the included peer-reviewed publications on iron monotherapy and the combination treatment with ESAs and iron, respectively, the study authors failed to properly report on study duration and patient follow-up time. Only 36% of the studies on the combination treatment with ESAs and iron certainly employed a follow-up period of at least 30 postoperative days. As a result, some longer-term AEs of these therapies (e.g. thromboembolic, cardiac AEs) may only have become apparent after follow-up of these patients had ended. A second independent important reason for the very low certainty of the evidence is the lack of systematic surveillance of pre-defined AE outcomes: just 5 studies (27, 47, 49, 55, 65) explicitly indicated that patients were systematically assessed for AEs or that AE recording was part of the study protocol, whereas the others probably used spontaneous report monitoring and/or reporting.

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

Moreover, there is heterogeneity in definitions and data collection methods used, as well as a lack of reporting on the exact methods used to ascertain the events. Thirdly, selective non-reporting bias is likely to have occurred, for example due to conflicts of interest: entire study reports may be unpublished due to the unexpected findings of harms, or alternatively, particular study results may be selectively unavailable (e.g. because the magnitude, direction or pvalue were considered unfavourable by the investigators). This may put the results of this review at risk, as these missing results may differ from the available results. Therefore, the results of these analyses should be interpreted with caution. Nevertheless, maximal effort has been put in to ensure minimal bias occurring at the review level by including both published and unpublished study data retrieved from an extensive array of databases and trial registries relevant to the topic of PBM, and by contacting study authors to request missing information. This systematic review has several other strengths. By adopting comprehensive selection criteria, the review has captured any possible AE that may (have) occur(red) during or after administration of iron and/or ESA therapy in preoperatively anaemic elective surgery patients. In contrast to most systematic reviews of RCTs only, observational studies were eligible as well. No effort was spared in contacting study authors to obtain additional data or clarification. Special attention was paid to inadequate monitoring and incomplete reporting, both pivotal issues in assessing risk of bias for AE data. Finally, the GRADE assessment was checked by a third independent methodological expert. To the best of our knowledge, this is the first systematic review to summarize the available direct evidence on potential AEs of iron and/or ESA therapy in preoperatively anaemic patients scheduled for any type of elective surgery. A previous systematic review on the use of ESAs (whether or not augmented with preoperative autologous blood donation) in anaemic patients undergoing elective hip, knee and spine orthopaedic surgery demonstrated that recombinant human erythropoietin was associated with an increased risk of deep vein thrombosis (Peto Odds Ratio: 1.66, 95%CI [1.10;2.48]), but was inconclusive regarding the risk of mortality, myocardial infarction and cerebrovascular accidents (71). In contrast, in a more recent systematic review that only included RCTs that investigated preoperative erythropoietin administration in adult surgical patients and contained data on allogeneic transfusions as their primary outcomes, an association between preoperative erythropoietin and an increased risk of

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

thromboembolic events could not be demonstrated (RR: 1.02, 95%CI [0.78;1.33], p=0.68) (72). In a third systematic review of RCTs investigating the combination therapy of ESAs and iron compared to iron monotherapy in adult surgical patients, an association could not be demonstrated between the combination therapy and an increased risk of deep vein thrombosis (RR: 1.48, 95%CI [0.95;2.31], p=0.09), pulmonary embolism, mortality, stroke, myocardial infarction or renal dysfunction (73). A recent Cochrane systematic review of RCTs comparing preoperative recombinant human erythropoietin plus iron therapy to control (placebo, no treatment, or standard of care with or without iron) in preoperatively anaemic adults undergoing non-cardiac surgery found moderate-certainty evidence indicating little or no difference in the risk of mortality within 30 days of surgery or of experiencing any adverse event (including local rash, fever, constipation, or transient hypertension) (74). Other prior systematic reviews on ESA safety have focused on other patient populations such as rheumatoid arthritis (75), chronic heart failure (76, 77), predialysis (78), chronic kidney disease (79) and critically-ill (80) patients. Similar to our review, these reviews concluded that the question of whether ESAs affect the risk of AEs in these patient populations remains unanswered. The very narrow scope of the population of interest (in our case preoperatively anaemic elective surgery patients) has certainly played a role in this, since it resulted in a limited number of included studies covering a wide range of AEs. A recent systematic review has shed light on the safety of perioperative iron administration. Gómez-Ramírez et al. synthetized the evidence on the efficacy and safety of short-term perioperative intravenous iron, with or without erythropoietin, in both elective and non-elective major orthopaedic surgery (81). In 10 of the 14 studies identified, only 25 adverse drug effects were reported in patients treated with intravenous iron, which consisted mainly of gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or constipation) and hypotension. There was no difference in the incidence of clinically relevant adverse drug effects in patients receiving iron, with or without EPO, compared to those assigned to control (1.13% vs. 0.85%; RR: 1.34, 95% CI[0.63;2.86], p=0.56). When focusing on elective surgery patients, one RCT and 3 observational studies were identified, of which 2 observational studies reported on 30-day mortality and infection rates. No statistically significant differences in postoperative infection rates were found. Mortality rates were 0 in both studies, hindering further statistical analysis. Similar to our review, a recent Cochrane systematic review of RCTs evaluating the effect of preoperative iron therapy (compared to placebo, no treatment, standard of care or another form of iron therapy) in anaemic patients undergoing surgery concluded that the effects on short-term mortality or postoperative morbidity (including infection and adverse events within 30 days) remain uncertain, and that the inclusion of new research in the future is therefore very likely to change the results (82). Other previous systematic reviews investigating the safety and tolerability of iron therapy (83-85) have generally employed broader selection criteria at the population level, in combination with narrow criteria at the intervention (e.g. comparing IV iron supplements to each other) and/or outcome level (i.e. limiting the number of AEs of interest). For example, a systematic review and meta-analysis by Tolkien revealed that oral ferrous sulfate therapy in patients with iron-deficiency anaemia is associated with significantly more gastrointestinal-specific side-effects, compared to IV iron or placebo (86). By including patients with iron-deficiency anaemia of any cause (e.g. chronic kidney disease, pregnancy, blood donation), the reviewers were able to meta-analyse data from 43 RCTs comprising 6831 adults. Therefore, future systematic review teams may benefit from employing broad selection criteria at the population level in combination with narrow intervention criteria. Expanding the population scope will facilitate the retrieval of AE data of regulated iron and ESA products published in regulatory agency databases (e.g. Food and Drug Administration AE Reporting System). If sufficient numbers of studies/data sources are included and significant heterogeneity is detected, the reviewers should consider performing subgroup analyses at the population level. However, in order to be able to perform systematic reviews and meta-analyses that provide highercertainty evidence that can influence decision-making in healthcare, further transparent postmarketing safety surveillance of iron and ESA products is warranted. In addition, authors of experimental studies on iron and/or ESA therapy should spend time thinking about expected AEs, how to measure and analyse them, and document this in an a priori (ideally published) protocol. They should keep track of expected and unexpected AEs and may want to consider providing all AE data online (e.g. in an End of Trial report, open-access) if reporting in a peer-reviewed publication is impeded by word limitations. Finally, publishers and funders should stress the importance of the collection, documenting and reporting of AEs and adopt rigorous conflict of interest policies.

Conclusions

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

In conclusion, it remains unclear if ESA and/or iron therapy is associated with the occurrence of AEs in preoperatively anaemic elective surgery patients. This uncertainty results from both low quantity and quality of AE data due to limitations in study design, data collection and reporting. List of abbreviations ΑE Adverse event CI Confidence interval **ESA** Erythropoiesis-stimulating agent **GRADE** Grading of Recommendations, Assessment, Development and Evaluation International Consensus Conference - Patient Blood Management ICC-PBM IV Intravenous **IQR** Interquartile range **PBM** Patient blood management **PICO** Population Intervention Comparison Outcome RCT Randomized controlled trial RoB Risk of Bias RR Risk Ratio WHO World Health Organization **Declarations** Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Availability of data and materials All data generated or analysed during this study are included in this published article and its additional files.

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

Competing interests Financial competing interests directly related to this review: PMM received personal fees from Ethos SrI (Advisory Board on PBM) and SUMMEET SrI (Speaker in a meeting on PBM). PM received grants from Vifor Pharma, SerumWerke Bernburg, csl Behring, Fresenius Medical, and B.Baun. PM received personal fees from Vifor Pharma and Pharmacosmos. HV, JL, BA, EDB, GB, JG, VC, YO and PV declared not having any relevant direct financial competing interest. Financial competing interests not directly related to this review: HV, JL, BA, EDB, VC and PV are employees of Belgian Red Cross-Flanders, which is responsible for supplying adequate quantities of safe blood products to hospitals in Flanders and Brussels on a continuous basis and is being paid for this activity by the Ministry of Social Affairs. Belgian Red Cross-Flanders received a grant from the European Blood Alliance to conduct this review. PMM received personal fees from Editree SrI (creation of training course on porphyria), Eleuthera SrI (AHP Advisory Board), Collage SpA (speaker in a meeting on Erythrocytosis), IQVIA (Advisory Board on porphyria), Alnylam (Advisory Board on porphyria). GB, JG, PM, YO declared not having any other financial competing interest. Non-financial competing interests: JL, HVR, BA, GB, PMM, YO, EDB, VC and PV declared not having any non-financial competing interests. PM declared to be involved in the implementation of PBM programs. JG declared to be involved in The Danish Health Authority-National Clinical Guideline-Indication for Transfusion with Blood Components-Copenhagen 2018 (https://www.sst.dk/da/udgivelser/2018/nkr-indikation-fortransfusion-med-blodkomponenter). **Funding** Funding for this project has been provided partly through an Agreement with the European Blood Alliance (EBA) and partly by the Foundation for Scientific Research of the Belgian Red Cross. The contents of this document do not necessarily reflect the views and policies of the EBA, nor does mentioning of trade names or commercial products constitute endorsement or recommendation of use.

Authors' contributions

617

625

626

634

635

636

- 618 JL: Investigation, Formal analysis, Writing Original draft, Visualization. HVR: Conceptualization,
- 619 Investigation, Formal analysis, Writing Original draft, Visualization, Supervision, Project
- 620 administration, Funding acquisition. BA: Validation, Writing Review & Editing. GB: Validation, Writing
- 621 Review & Editing. JG: Validation, Writing Review & Editing. PMM: Validation, Writing Review &
- 622 Editing. PM: Validation, Writing Review & Editing. YO: Validation, Writing Review & Editing. EDB:
- 623 Conceptualization, Writing Review & Editing, Supervision. VC: Conceptualization, Writing Review
- 624 & Editing. PV: Conceptualization, Resources, Writing Review & Editing, Supervision.

Acknowledgements

- 627 We are grateful to study authors Prof. Dr. Andrea Steinbicker, Dr. Emmanuel Rineau, Dr. Edel Quinn,
- 628 Dr. Yunhwan Kim, Prof. Dr. Christoph Kettelhack, Prof. Dr. Niels Qvist, Prof. Dr. Cynthia So-Osman,
- 629 Dr. Philip Ming Ho Kam, Dr. Andrew Klein, Mr. Sandip Nandhra, and Prof. Dr. Patrick Meybohm (also
- a co-author for this review), for providing additional data and information. We thank Dr. Daniela
- 631 Junqueira (Cochrane Adverse Effects Methods Group) for the helpful methodological discussions and
- 632 guidance, and Ehsan Sadeghian and Olga Krasnoukhova for helping us screen Persian and Russian
- 633 papers, respectively.

References

- 1. (WHO) WHO. WHO Global Forum for Blood Safety: Patient blood management 2011
- [Available from: https://www.who.int/bloodsafety/events/gfbs_01_pbm/en/ (Last accessed June 5
- 639 2020).
- 640 2. Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R, et al. Patient
- Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA.
- 642 2019;321(10):983-97.
- 3. Van Remoortel H, Aranko K, Mueller MM, De Buck E, Devine D, Follea G, et al. The
- 644 systematic use of evidence-based methodologies and technologies enhances shared decision-making

- 645 in the 2018 International Consensus Conference on Patient Blood Management. Vox Sang.
- 646 2020;115(1):60-71.
- 4. Benoist S, Panis Y, Pannegeon V, Alves A, Valleur P. Predictive factors for perioperative
- 648 blood transfusions in rectal resection for cancer: A multivariate analysis of a group of 212 patients.
- 649 Surgery. 2001;129(4):433-9.
- 5. Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an
- 651 independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res.
- 652 2002;102(2):237-44.
- 653 6. Leichtle SW, Mouawad NJ, Lampman R, Singal B, Cleary RK. Does preoperative anemia
- adversely affect colon and rectal surgery outcomes? J Am Coll Surg. 2011;212(2):187-94.
- 7. Padmanabhan H, Siau K, Curtis J, Ng A, Menon S, Luckraz H, et al. Preoperative Anemia and
- Outcomes in Cardiovascular Surgery: Systematic Review and Meta-Analysis. Ann Thorac Surg.
- 657 2019;108(6):1840-8.
- 658 8. Van Remoortel H, Laermans J, Avau B, Bekkering G, Georgsen J, Manzini PM, et al.
- 659 Effectiveness of Iron Supplementation With or Without Erythropoiesis-Stimulating Agents on Red
- 660 Blood Cell Utilization in Patients With Preoperative Anaemia Undergoing Elective Surgery: A
- Systematic Review and Meta-Analysis. Transfus Med Rev. 2021;35(2):103-24.
- 9. Avau B, Van Remoortel H, Laermans J, Bekkering G, Fergusson D, Georgsen J, et al. Lack of
- 663 Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic,
- 664 Elective Surgery Patients: A Systematic Review and Updated Analysis. PharmacoEconomics.
- 665 2021; Accepted for publication.
- 10. CEBaP. Development of evidence-based guidelines and systematic reviews: methodological
- 667 charter 2020 [Available from: https://www.cebap.org/storage/cebap/inf-methodology-charter-cebap.pdf
- 668 (Last accessed June 5 2020).
- 669 11. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms
- 670 checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157.
- 671 12. Peryer G GS, Junqueira D, Vohra S, Loke YK. Chapter 19: Adverse effects. 2019. In:
- 672 Cochrane Handbook for Systematic Reviews of Interventions version 60 (updated July 2019)
- [Internet]. Cochrane. Available from: www.training.cochrane.org/handbook.

- 674 13. Szebeni J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, et al. Hypersensitivity to
- 675 intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol.
- 676 2015;172(21):5025-36.
- 677 14. Thomas J BJ, Graziosi S EPPI-Reviewer 4: software for research synthesis. 2010. p. EPPI-
- 678 Centre Software. London: Social Science Research Unit, UCL Institute of Education.
- 679 15. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March
- 2011]: The Cochrane Collaboration; 2011. Available from: http://handbook-5-1.cochrane.org/.
- 681 16. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised
- tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
- 683 17. [Available from: https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2
- 684 (Last accessed on July 29 2020).
- 18. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of
- evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
- 687 19. Centre CTNC. Review Manager (RevMan) [Computer program]. Version 5.3. The Cochrane
- 688 Collaboration; 2014.
- 689 20. McKenzie JE BS. Chapter 12: Synthesizing and presenting findings using other methods.
- 2019. In: Cochrane Handbook for Systematic Reviews of Interventions version 60 (updated July 2019)
- [Internet]. Cochrane. Available from: Available from www.training.cochrane.org/handbook.
- 692 21. Holger J Schünemann GEV, Julian PT Higgins, Nancy Santesso, Jonathan J Deeks, Paul
- 693 Glasziou, Elie Akl, Gordon H Guyatt; on behalf of the Cochrane GRADEing Methods Group. Chapter
- 694 15: Interpreting results and drawing conclusions. 2019. In: Cochrane Handbook for Systematic
- 695 Reviews of Interventions version 60 (updated July 2019) [Internet]. Cochrane. Available from:
- 696 www.training.cochrane.org/handbook.
- 697 22. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26:
- 698 informative statements to communicate the findings of systematic reviews of interventions. J Clin
- 699 Epidemiol. 2020;119:126-35.
- 700 23. Biboulet P, Bringuier S, Smilevitch P, Loupec T, Thuile C, Pencole M, et al. Preoperative
- 701 Epoetin-alpha with Intravenous or Oral Iron for Major Orthopedic Surgery: A Randomized Controlled
- 702 Trial. Anesthesiology. 2018;129((4):):710-20.

- 703 24. Cao SL, Ren Y, Li Z, Lin J, Weng XS, Feng B. Clinical effectiveness of 3 days preoperative
- treatment with recombinant human erythropoietin in total knee arthroplasty surgery: a clinical trial.
- 705 QJM. 2020;113(4):245-52.
- 706 25. Christodoulakis M, Tsiftsis DD, Hellenic Surgical Oncology P, Group EPOS. Preoperative
- 707 epoetin alfa in colorectal surgery: a randomized, controlled study. Annals of Surgical Oncology.
- 708 2005;12((9):):718-25.
- 709 26. de Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC. Baseline hemoglobin as a
- 710 predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. American
- 711 Journal of Orthopedics. 1996;25((8):):533-42.
- 712 27. Dickson EA, Keeler BD, Ng O, Kumar A, Brookes MJ, Acheson AG, et al. Preoperative
- 713 intravenous iron therapy and survival after colorectal cancer surgery: long-term results from the IVICA
- 714 randomised controlled trial. Colorectal Dis. 2020.
- 715 28. Dousias V, Paraskevaidis E, Dalkalitsis N, Tsanadis G, Navrozoglou I, Lolis D. Recombinant
- 716 human erythropoietin in mildly anemic women before total hysterectomy. Clinical and Experimental
- 717 Obstetrics & Gynecology. 2003;30((4):):235-8.
- 718 29. Dousias V, Stefos T, Navrozoglou I, Staikos I, Ditto A, Paraskevaidis E. Administration of
- 719 recombinant human erythropoietin in patients with gynecological cancer before radical surgery.
- 720 Clinical and Experimental Obstetrics & Gynecology. 2005;32((2):):129-31.
- 721 30. Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The Important Role for
- 722 Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: a
- 723 Randomized Controlled Trial. Annals of surgery. 2016;264(1):41-6.
- 724 31. Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandez R, et al. Perisurgical
- 725 erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study.
- 726 Surgery. 1996;119(5):523-7.
- 727 32. Keeler BD, Dickson EA, Simpson JA, Ng O, Padmanabhan H, Brookes MJ, et al. The impact
- 728 of pre-operative intravenous iron on quality of life after colorectal cancer surgery: outcomes from the
- 729 intravenous iron in colorectal cancer-associated anaemia (IVICA) trial. Anaesthesia. 2019;74(6):714-
- 730 25.

- 731 33. Keeler BD, Simpson JA, Ng O, Padmanabhan H, Brookes MJ, Acheson AG. Randomized
- 732 clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br
- 733 J Surg. 2017;104(3):214-21.
- 734 34. Kettelhack C, Hones C, Messinger D, Schlag PM. Randomized multicentre trial of the
- 735 influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in
- 736 anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg. 1998;85(1):63-7.
- 737 35. Khalafallah A A-BA, Chan J, Sung MF, Bates G, Ahuja KDK, Batten JC, Einoder B. A
- 738 Prospective Randomized Controlled Trial to Assess the Effect of Intravenous versus Oral Iron Therapy
- 739 in the Treatment of Orthopaedic Preoperative Anaemia. J Blood Disorders Transf. 2012;3(4):
- 740 1000127.
- 741 36. Kim YH, Chung HH, Kang SB, Kim SC, Kim YT. Safety and usefulness of intravenous iron
- 342 sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-
- 743 label, prospective, randomized study. Acta Haematol. 2009;121(1):37-41.
- 744 37. Kosmadakis N, Messaris E, Maris A, Katsaragakis S, Leandros E, Konstadoulakis MM, et al.
- 745 Perioperative Erythropoietin Administration in Patients with Gastrointestinal Tract Cancer: Prospective
- 746 Randomized Double-Blind Study. Annals of Surgery. 2003;237(3):417-21.
- 747 38. Larson B, Bremme K, Clyne N, Nordstrom L. Preoperative treatment of anemic women with
- epoetin beta. Acta Obstet Gynecol Scand. 2001;80(6):559-62.
- 749 39. Lee SH, Shim JK, Soh S, Song JW, Chang BC, Lee S, et al. The effect of perioperative
- 750 intravenously administered iron isomaltoside 1000 (Monofer(R)) on transfusion requirements for
- 751 patients undergoing complex valvular heart surgery: study protocol for a randomized controlled trial.
- 752 Trials. 2018;19(1):350.
- 753 40. Olijhoek G, Megens JGN, Musto P, Nogarin L, Gassmann-Mayer C, Vercammen E, et al. Role
- 754 of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: A randomized,
- placebo-controlled trial. Transfusion. 2001;41(7):957-63.
- 756 41. Padmanabhan H, Siau K, Nevill AM, Morgan I, Cotton J, Ng A, et al. Intravenous iron does not
- 757 effectively correct preoperative anaemia in cardiac surgery: a pilot randomized controlled trial.
- 758 Interactive Cardiovascular and Thoracic Surgery. 2018.
- 759 42. Qvist N, Boesby S, Wolff B, Hansen CP. Recombinant human erythropoietin and hemoglobin
- 760 concentration at operation and during the postoperative period: reduced need for blood transfusions in

- 761 patients undergoing colorectal surgery--prospective double-blind placebo-controlled study. World J
- 762 Surg. 1999;23(1):30-5.
- 763 43. Qvist N, Boesby S, Wolff B, Hansen CP. [Perioperative administration of recombinant human
- 764 erythropoietin in colorectal cancer surgery. A prospective, randomized, double-blind placebo
- 765 controlled study]. Ugeskr Laeger. 2000;162(3):355-8.
- 766 44. Richards T, Baikady RR, Clevenger B, Butcher A, Abeysiri S, Chau M, et al. Preoperative
- 767 intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised,
- double-blind, controlled trial. Lancet. 2020.
- 769 45. Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH. The effects of epoetin alfa on
- transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-
- 771 controlled study. Laryngoscope. 2002;112(7 Pt 1):1221-9.
- 772 46. So-Osman C, Nelissen RG, Koopman-van Gemert AW, Kluyver E, Poll RG, Onstenk R, et al.
- Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized
- 774 controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive
- transfusion policy in erythropoietin-eligible patients. Anesthesiology. 2014;120(4):839-51.
- 776 47. Stowell CP, Jones SC, Enny C, Langholff W, Leitz G. An open-label, randomized, parallel-
- 777 group study of perioperative epoetin alfa versus standard of care for blood conservation in major
- elective spinal surgery: Safety analysis. Spine. 2009;34(23):2479-85.
- 779 48. Urena M, Del T, Altisent OA, Campelo-Prada F, Regueiro A, DeLarochellière R, et al.
- 780 Combined erythropoietin and iron therapy for anaemic patients undergoing transcatheter aortic valve
- 781 implantation: the EPICURE randomised clinical trial. EuroIntervention. 2017;13(1):44-52.
- 782 49. Weltert L, Rondinelli B, Bello R, Falco M, Bellisario A, Maselli D, et al. A single dose of
- 783 erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-
- 784 blind randomized controlled trial. Transfusion. 2015;55(7):1644-54.
- 785 50. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human
- 786 erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing
- valvular heart surgery. Anesthesiology. 2011;115(5):929-37.
- 788 51. Cladellas M, Farré N, Comín-Colet J, Gómez M, Meroño O, Bosch MA, et al. Effects of
- 789 preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve
- 790 replacement. American Journal of Cardiology. 2012;110(7):1021-6.

- 791 52. Delasotta LA, Rangavajjula A, Frank ML, Blair J, Orozco F, Ong A. The Use of Preoperative
- 792 Epoetin-alpha in Revision Hip Arthroplasty. Open Orthop J. 2012;6:179-83.
- 793 53. Delasotta LA, Rangavajjula AV, Frank ML, Blair JL, Orozco FR, Ong AC. The Use of Epoetin-
- alpha in Revision Knee Arthroplasty. Advances in Orthopedics. 2012.
- 795 54. Ellermann I, Bueckmann A, Eveslage M, Buddendick H, Latal T, Niehoff D, et al. Treating
- 796 Anemia in the Preanesthesia Assessment Clinic: Results of a Retrospective Evaluation. Anesthesia
- 797 and Analgesia. 2018;127(5):1202-10.
- 798 55. Evans CR, Jones R, Phillips G, Greene G, Phillips M, Morris-Clarke R. Observational study of
- 799 pre-operative intravenous iron given to anaemic patients before elective cardiac surgery. Anaesthesia.
- 800 2021.
- 801 56. Kam PM, Chu CW, Chan EM, Liu OL, Kwok KH. Use of intravenous iron therapy in colorectal
- cancer patient with iron deficiency anemia: a propensity-score matched study. Int J Colorectal Dis.
- 803 2020;35(3):521-7.
- 804 57. Klein AA, Chau M, Yeates JA, Collier T, Evans C, Agarwal S, et al. Preoperative intravenous
- iron before cardiac surgery: a prospective multicentre feasibility study. Br J Anaesth. 2020;124(3):243-
- 806 50.
- 807 58. Laso-Morales M, Jericó C, Gómez-Ramírez S, Castellví J, Viso L, Roig-Martínez I, et al.
- 808 Preoperative management of colorectal cancer-induced iron deficiency anemia in clinical practice:
- data from a large observational cohort. Transfusion. 2017;57(12):3040-8.
- 810 59. Nandhra S, Chau M, Klein AA, Yeates JA, Collier T, Evans C, et al. Preoperative anaemia
- 811 management in patients undergoing vascular surgery. Br J Surg. 2020;107(12):1558-61.
- 812 60. Pinilla-Gracia C, Mateo-Agudo J, Herrera A, Munoz M. On the relevance of preoperative
- 813 haemoglobin optimisation within a Patient Blood Management programme for elective hip arthroplasty
- 814 surgery. Blood Transfus. 2020;18(3):182-90.
- 815 61. Quinn EM, Meland E, McGinn S, Anderson JH. Correction of iron-deficiency anaemia in
- 816 colorectal surgery reduces perioperative transfusion rates: A before and after study. Int J Surg.
- 817 2017;38:1-8.
- 818 62. Rineau E, Stoyanov A, Samson E, Hubert L, Lasocki S. Patient Blood Management in Major
- 819 Orthopedic Surgery: Less Erythropoietin and More Iron? Anesth Analg. 2017;125(5):1597-9.

- 820 63. Triphaus C, Judd L, Glaser P, Goehring MH, Schmitt E, Westphal S, et al. Effectiveness of
- 821 Preoperative Iron Supplementation in Major Surgical Patients with Iron Deficiency: A Prospective
- 822 Observational Study. Ann Surg. 2019.
- 823 64. Wilson MJ, Dekker JW, Bruns E, Borstlap W, Jeekel J, Zwaginga JJ, et al. Short-term effect of
- 824 preoperative intravenous iron therapy in colorectal cancer patients with anemia: results of a cohort
- 825 study. Transfusion. 2018;58(3):795-803.
- 826 65. Wilson MJ, Dekker JWT, Buettner S, Harlaar JJ, Jeekel J, Schipperus M, et al. The effect of
- 827 intravenous iron therapy on long-term survival in anaemic colorectal cancer patients: Results from a
- 828 matched cohort study. Surg Oncol. 2018;27(2):192-9.
- 829 66. Ye Z WJ, Wang Q, Wang Q, Han L, Ulain Q, Batchu N, Song Q, Li X, Li Q. Perioperative
- 830 administration of erythropoietin combined with iron sucrose in gynecological tumor patients: a
- retrospective study. Int J Clin Exp Med 2017;10(4):7111-6.
- 832 67. UMC. The use of the WHO-UMC system for standardised case causality assessment The
- 833 World Health Organization Uppsala Monitoring Centre; 2015 [Available from:
- 834 https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
- 835 (Last accessed July 27 2020).
- 836 68. Gomez-Ramirez S, Shander A, Spahn DR, Auerbach M, Liumbruno GM, Vaglio S, et al.
- 837 Prevention and management of acute reactions to intravenous iron in surgical patients. Blood
- 838 Transfus. 2019;17(2):137-45.
- 839 69. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al. Comparative Risk of
- 840 Anaphylactic Reactions Associated With Intravenous Iron Products. JAMA. 2015;314(19):2062-8.
- 841 70. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines
- 842 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64(12):1283-93.
- 843 71. Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, et al. Detection,
- 844 evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient:
- 845 NATA guidelines. Br J Anaesth. 2011;106(1):13-22.
- 846 72. Cho BC, Serini J, Zorrilla-Vaca A, Scott MJ, Gehrie EA, Frank SM, et al. Impact of
- 847 Preoperative Erythropoietin on Allogeneic Blood Transfusions in Surgical Patients: Results From a
- 848 Systematic Review and Meta-analysis. Anesth Analg. 2019;128(5):981-92.


- 849 73. Kei T, Mistry N, Curley G, Pavenski K, Shehata N, Tanzini RM, et al. Efficacy and safety of
- 850 erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic
- 851 review and meta-analysis. Can J Anaesth. 2019;66(6):716-31.
- 852 74. Kaufner L, von Heymann C, Henkelmann A, Pace NL, Weibel S, Kranke P, et al.
- 853 Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic
- adults undergoing non-cardiac surgery. Cochrane Database Syst Rev. 2020;8:CD012451.
- 855 75. Marti-Carvajal AJ, Agreda-Perez LH, Sola I, Simancas-Racines D. Erythropoiesis-stimulating
- agents for anemia in rheumatoid arthritis. Cochrane Database Syst Rev. 2013(2):CD000332.
- 857 76. Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H. Harms of off-label
- 858 erythropoiesis-stimulating agents for critically ill people. Cochrane Database Syst Rev.
- 859 2017;8:CD010969.
- 860 77. Ngo K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, et al.
- 861 Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database
- 862 Syst Rev. 2010(1):CD007613.
- 863 78. Hahn D, Esezobor CI, Elserafy N, Webster AC, Hodson EM. Short-acting erythropoiesis-
- 864 stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev.
- 865 2017;1:CD011690.
- 79. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-
- 867 stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
- 868 Cochrane Database Syst Rev. 2014(12):CD010590.
- 869 80. Litton E, Latham P, Inman J, Luo J, Allan P. Safety and efficacy of erythropoiesis-stimulating
- 870 agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-
- analysis. Intensive Care Med. 2019;45(9):1190-9.
- 872 81. Gomez-Ramirez S, Maldonado-Ruiz MA, Campos-Garrigues A, Herrera A, Munoz M. Short-
- 873 term perioperative iron in major orthopedic surgery: state of the art. Vox Sang. 2019;114(1):3-16.
- 874 82. Ng O, Keeler BD, Mishra A, Simpson JA, Neal K, Al-Hassi HO, et al. Iron therapy for
- preoperative anaemia. Cochrane Database Syst Rev. 2019;12:CD011588.
- 876 83. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous
- 877 iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12-23.

- 878 84. Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, Haya-Palazuelos J, Ciria-Recasens M,
- Manasanch J, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res
- 880 Opin. 2013;29(4):291-303.
- 881 85. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing
- 882 requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised
- 883 clinical trials. BMJ. 2013;347:f4822.
- 884 86. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation
- 885 causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS
- 886 One. 2015;10(2):e0117383.


888

Additional files


- 889 Additional file 1. Completed PRISMA harms checklist.
- 890 Additional file 2. Supplementary tables.







B



Α

medRxiv preprint doi: https://doworg/10.1101/2022.03.21.22272600; this version posted March 22, 2022. The copyright holder for this pre (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.

(which was no	t cert	ified		er rev	view) made	is the availa	authorable ur
	Random sequence generation (selection blas)	Allocation concealment (selection bias)	Blinding of participants and personnel (performanc	Incomplete outcome data (attrition bias)	Inadequate measurement of the outcomes	Inadequate selection of the reported results	Other bias
Biboulet 2018	•	•	•	•			•
Cao 2020	•	?	•	•		•	•
Christodoulakis 2005	?	?	•	•	•		•
De Andrade 1996	•	?	•	•	•		•
Dickson 2020	•	•	•	•	•	•	•
Dousias 2003	•	?	•	?	•	•	•
Dousias 2005	•	•	•	?			•
Froessler 2016	•	•	•	•	•	•	•
Heiss 1996	?	?	?	•	•		•
Keeler 2017	•	•	•	•	•	•	•
Keeler 2019	•	•	?	•	•		•
Kettelhack 1998	?	?	?	•			•
Khalafallah 2012	•	?	?	•			•
Kim 2009	•	?	?	•			•
Kosmadakis 2003	?	?	?	•		•	•
Larson 2001	?	?	?	•			•
Lee 2019	•	?	•	•			•
Olijhoek 2001	•	?	•	•			•
Padmanabhan 2019	?	•					•
Qvist 1999/2000	•	•	?	•			•
Richards 2020	•	•	•	•			•
Scott 2002	?	?	•	•			•
So-Osman 2014	•	•	•	•			•
Stowell 2009	•			•		•	•
Urena 2017	•	•	?	•			•
Weltert 2015	•	•	•	•	•		•
Yoo 2011	•	•	?	•	•		•

BY-NC-ŇD 4.0 Internat	Inappropriate eligibility criteria	Inappropriate methods for exposure and outcome value	Inadequate measurement of the outcomes	Inadequate selection of the reported result	Not controlled for confounding	Incomplete or inadequate follow-up	Other limitations
Cladellas 2012		•		•		•	•
Delasotta 2012_A	?	•	•			•	•
Delasotta 2012_B	?	•	•			•	•
Ellerman 2018	?	•	•	•		•	•
Evans 2021		•	•	•		•	•
Kam 2020	•	•	•	•	•	•	•
Klein 2020	•	•	•		•	•	•
Laso-Morales 2017	?	•	•			•	•
Nandhra 2020			•			•	•
Pinilla-Gracia 2020		•				•	•
Quinn 2017	?	•				•	•
Rineau 2017		•	•		•	•	•
Triphaus 2019	?	•				•	•
Wilson 2018_A		•	•		•	•	•
Wilson 2018_B	•	•	•	•	•	•	•
Ye 2017	•	•				•	•

